News and Events

The HIV care landscape is constantly evolving, with breakthroughs in the methods, strategies and treatments to control and prevent transmission. This section aims to provide timely news updates and clinically relevant information about HIV disease management to clinicians who are actively involved in HIV care.

Upcoming events such as conferences, online seminars and continuing education programs will be listed here on a regular basis.

2nd October 2018

Guideline recommendations

Key recommendations from the latest EACS and DHHS guidelines for DESCOVY®▼ (emtricitabine / tenofovir alafenamide) are listed below, with links to the full publications.

2nd October 2018

Key facts

Please click on the tabs below to find recommendations on how to prescribe DESCOVY®▼ (emtricitabine / tenofovir alafenamide). Full details of the information can be found in the DESCOVY® Summary of Product Characteristics.

2nd October 2018

Safety and tolerability

The safety data for DESCOVY®▼ (emtricitabine / tenofovir alafenamide) is based on data from all phase 2 and 3 studies, involving >3,000 HIV-positive individuals receiving FTC/TAF.1

2nd October 2018

Efficacy and resistance

The clinical evidence to support DESCOVY®▼ (emtricitabine / tenofovir alafenamide) in combination with other antiretroviral agents for the treatment of HIV is based on studies conducted with FTC and TAF when given with boosted EVG as the fixed-dose combination tablet E/C/F/TAF,1-5 and data from a phase 3 trial in virologically suppressed adults with HIV infection. 6-8

2nd October 2018

DESCOVY®▼

DESCOVY® is a fixed-dose combination tablet containing emtricitabine (FTC) and tenofovir alafenamide (TAF). Together, they form a nucleoside reverse transcriptase inhibitor (NRTI) backbone.1,2